Selected Papers from 21st International Conference on Progress in Vaccination Against Cancer (PIVAC-22)

Submission deadline: 30 December 2022
Special Issue Editors
  • Federica Cavallo, PhD
    Department of Molecular Biotechnology and Health Sciences "Guido Tarone", University of Torino, Turin, Italy
    Interests: immunotherapy; tumor immunology; oncoantigens; cancer vaccines; cancer stem cells; preclinical models of cancer; tumor microenvironment
  • Elena Quaglino, PhD
    Department of Molecular Biotechnology and Health Sciences "Guido Tarone", University of Torino, Turin, Italy
    Interests: immunotherapy; tumor immunology; oncoantigens; cancer vaccines; cancer stem cells; preclinical models of cancer; tumor microenvironment
  • Laura Conti, PhD
    Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center "Guido Tarone", University of Torino, Turin, Italy
    Interests: immunotherapy; tumor immunology; oncoantigens; cancer vaccines; cancer stem cells; preclinical models of cancer; tumor microenvironment
Special Issue Information

Dear Colleagues,

Despite remarkable advances in the field of immunotherapy have improved patient outcomes, cancer mortality due to therapy resistance and metastatic spread still represents an unsolved problem. Current studies demonstrate that a deeper understanding of the cross-talk between cancer and immune cells in the tumor microenvironment would be central to ameliorating patients’ outcomes.

To this aim, this special issue will feature research articles and reviews focused on topics presented and discussed at the 21st International Conference on Progress in Vaccination Against Cancer (PIVAC-22), which will be held in Torino (Italy) from 26th to 28th September 2022. The contributions will cover the most recent advances in the field of cancer immunotherapy, with a focus on the tumor microenvironment, addressing how alterations to its molecular and metabolic features and to the microbiota impact the response to immunotherapy. Such knowledge could represent the basis for the rational design of new immunotherapeutic and combined strategies for cancer patients’ treatment and for the identification of novel immunotherapeutic targets to monitor patients’ immune responses.

Prof. Federica Cavallo, Prof. Laura Conti and Prof. Elena Quaglino

Guest Editors

Keywords
cancer vaccination
tumor microenvironment
immune suppression
tumor resistance to therapy
tumor immune escape
tme reprogramming
immunotherapy
tumor-infiltrating cells
biomarkers
cytokines
immune checkpoint inhibitors
microbiota
cancer metabolism
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.

Back to top